

CURRICULUM VITAE

Name: Arifulla Khan, MD

Address: Northwest Clinical Research Center
1951 152nd Place NE Suite 200
Bellevue, WA 98007
Phone: (425) 453-0404
Fax: (425) 453-1033
E-mail: akhan@nwcrc.net

Education: National College (1967-1969) Pre-Medical Entrance Course
Bangalore, India
Bangalore Medical College (1969-1975) Pre-Medical Entrance Course
Bangalore University, India

Qualifications: MBBS, Bangalore University, India, 1975
ECFMG, 1976
Visa Qualifying Examination, 1979
FLEX, 1982
American Board of Psychiatry and Neurology, 1987

Licensure: Indian Medical Council (Karnataka State) #14, 297
Washington State - #MD00021545

Clinical and Academic Experience:

9/75 - 9/76 Intern, Victoria and Combined Hospitals
Bangalore University, India

9/77 - 9/81 Psychiatric Registrar
Christchurch Clinical School
University of Otago
Christchurch, New Zealand

10/81 - 6/84 Resident/Chief Resident
Department of Psychiatry
University of Connecticut
Farmington, Connecticut

10/84 - 8/87 Medical Director
Voluntary Psychiatric Inpatient Unit

Harborview Medical Center, Seattle, WA

11/84 - 6/90 Assistant Professor, Department of Psychiatry
University of Washington, Seattle, WA

9/87 - 6/88 Medical Director, Inpatient Psychiatry Service
Harborview Medical Center, Seattle, WA

6/88 -
Present Examiner/Senior Examiner, American Board of Psychiatry
and Neurology (Part II)

7/88 - 1/95 Medical Director, Inpatient Psychiatry Service
University of Washington Medical Center
Seattle, WA

7/90 - 6/95 Associate Professor, Department of Psychiatry
University of Washington, Seattle, WA

7/92 - 1/95 Associate Medical Director
University of Washington Medical Center
Seattle, WA

4/95 -
Present Medical Director
Northwest Clinical Research Center
Northwest Medical Education, Inc
Bellevue, WA

6/95 – 01/06 Medical Staff at Overlake Hospital Medical Center
1035 – 116th Ave.NE
Bellevue, WA 98004

6/95 - 2012 Research Affiliate/Consultant and Courtesy Medical Staff
BHC Fairfax Hospital
10200 NE 132nd St.
Kirkland, WA 98034

2/97 - 12/02 Clinical Associate Professor
Department of Psychiatry and Behavioral Sciences
University of Washington, Seattle, WA

10/00 -
11/2005 Adjunct Associate Professor
Department of Psychiatry and Behavioral Sciences
Duke University School of Medicine, Durham, NC

12/05 - Present	Adjunct Professor Department of Psychiatry and Behavioral Sciences Duke University School of Medicine, Durham, NC
2009 - 2014	Medical Director Columbia Northwest Pharmaceuticals, LLC Bellevue, Washington
2010 - 2012	Medical Director Rhine Pharmaceuticals, LLC Bellevue, Washington
2018 - Present	Adjunct Professor, Clinical Medicine Pacific Northwest University Yakima, WA

Grants, Awards, and Research Experience:

6/84	Sandoz Award for superior academic achievement Department of Psychiatry, University of Connecticut
9/84 - 2/90	Clinical psychopharmacology sub-investigator in depressive disorders, Psychiatric Research Unit, Harborview Medical Center and University of Washington (PI - D. Dunner, MD)
3/85	Principal Investigator, Biomedical Research Support Grant from University of Washington for the study of treatment response to various antidepressants and placebo
8/87	Travel fellowship from the American College of Neuropsychopharmacology (ACNP)
10/88	Principal Investigator, ECT vs. pharmacotherapy in psychotic Depression (R01 application, approved, not funded)
1/89-12/89	Co-Investigator, Sleep changes in Early Alzheimer's Disease (PI- Patricia Prinz, PhD, MHR01-33688)
3/91 - 10/91	Principal Investigator, the Washington Institute for Mental Illness Research and Training Grant for TRH in ECT and ECS

1/92 - 12/92 Principal Investigator, The Alcohol and Drug Abuse Institute, University of Washington, Grant for TRH in Cognitively Impaired Alcoholics

6/94 Principal Investigator, Treatment of Depression Using Low-level Electrical Current or Alternating Magnetic Fields (patent filed)

3/90 - Present *Principal Investigator Phase I, II, III and IV Psychopharmacology Studies in depression, treatment resistant depression, generalized anxiety disorder, insomnia, bipolar mood disorder, schizophrenia, Alzheimer's disease, migraine, irritable bowel syndrome, post traumatic stress disorder, social anxiety disorder, attention deficit/hyperactivity disorder, female hypoactive sexual desire disorder, pediatric depression, pediatric bipolar mood disorder, pediatric attention deficit/hyperactivity disorder, pain, obsessive compulsive disorder, geriatric depression, geriatric generalized anxiety disorder*

3/01- present Extramural Reviewer, SBIR proposals, Ad Hoc committees, National Institute of Mental Health

3/05 Thomson Essential Science Indicators recognizing two publications (#66 and #81) receiving top 1% of citations between 2000 and 2004 suggesting 'extraordinary career accomplishment'

11/06 - 7/17 Member of the Board of Directors American College of Clinical Psychopharmacology

01/10 - Present Life Fellow American Psychiatric Association

11/10 Columbia Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act for Treatment of Suicidality in Depressed Patients Using Lithium in Combination with SSRI Therapy, \$244,479.25

11/10 Columbia Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act Grant for Treatment of PTSD Using Carvedilol, \$244,479.25

11/10 Rhine Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act for Synthesis and Development of the Bupropion r-enantiomer, \$244,479.25

Academic Memberships and Related Activities:

American Medical Association
American Psychiatric Association
American College of Clinical Psychopharmacology
King County Medical Society

Journal Editorial Board Member:

Psychiatry Journal, Hindawi Publications

Journal Reviewer:

Acta Psychiatrica Scandinavica
American Journal of Cardiology
American Journal of Psychiatry
Annals of General Hospital Psychiatry
Archives of General Psychiatry
Biomed Central
Bipolar Disorders
Biological Psychiatry
BMC Medicine
BMC Psychiatry
British Medical Journal (BMJ)
Clinical Schizophrenia and Related Psychoses
CNS Neuroscience and Therapeutics
Controlled Clinical Trials (Elsevier)
Convulsive Therapy
Depression and Anxiety
Expert Opinion on Pharmacotherapy
European Psychiatry
Human Psychopharmacology: Clinical and Experimental
International Clinical Psychopharmacology
International Journal of Environmental Research and Public Health
International Journal of Neuropsychopharmacology
Journal of Affective Disorders
Journal of the American Medical Association (JAMA)
Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology
Journal of the European Academy of Dermatology and Venereology
Journal of General Internal Medicine
Journal of Mind Body Regulation
Journal of Nervous and Mental Disease

Journal of Neural Transmission
Journal of Psychiatric Research
Journal of Psychopharmacology
Journal of Schizophrenia and Related Psychoses
Journal of Studies on Alcohol and Drugs
Lancet
Neuropsychiatric Disease and Treatment
Neuropsychopharmacology
PLOS One
Postgraduate Medicine
Progress in Neuro-psychopharmacology and Biological Research
Psychiatry Research
Psychological Medicine
Systematic Reviews

Publications:

1. **Khan A**, Joyce P, Jones A. Benzodiazepine withdrawal syndromes. *New Zealand Medical Journal*. 1980;92(665):94-96.
2. **Khan A**, Hornblow A, Walshe JWB. Benzodiazepine dependence: a general practice survey. *New Zealand Medical Journal*. 1981;94(687):19-21.
3. Joyce P, **Khan A**, Jones A. The revolving door patient. *Comprehensive Psychiatry*. 1984;22:397-403.
4. **Khan A**, Ciraulo DA, Nelson WH, Becker JT, Nies A, Jaffe J. Dexamethasone suppression test in recently detoxified alcoholics: clinical implications. *Journal of Clinical Psychopharmacology*. 1984;4(2):94-97.
5. Nelson WH, **Khan A** Orr WW. Delusional depression: phenomenology, neuroendocrine function, and tricyclic antidepressant response. *Journal of Affective Disorders*. 1984;6(3-4):297-306.
6. Nelson WH, **Khan A**, Orr WW, Tamragouri RN. The dexamethasone suppression test: interaction of diagnosis, sex and age in psychiatric patients. *Biological Psychiatry*. 1984;19:1293-1304.
7. Reik L, Smith L, **Khan A**, Nelson WH. Demyelinating encephalopathy in Lyme disease. *Neurology*. 1985;35:267-269.
8. **Khan A**, Jaffe J, Nelson WH, Morrison B. Resolution of neuroleptic malignant syndrome with dantrolene sodium: case report. *Journal of Clinical Psychiatry*. 1985;46:244-246.
9. **Khan A**, Nies A, Johnson GA, Becker JT. Plasma catecholamines and ECT. *Biological Psychiatry*. 1985;20:799-804.
10. Nelson WH, Sullivan P, **Khan A**, Tamragouri RN. The effects of age on dexamethasone suppression test results in alcoholic patients. *American Journal of Psychiatry*. 1986;143:237-239.
11. **Khan A**, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner DL. Platelet MAO-B activity in anxiety and depression. *Biological Psychiatry*. 1986;21:847-849.

12. Dager S, **Khan A**, Comess K, Raisys V, Dunner DL. Mitral valve abnormalities and catecholamine activity in anxious patients. *Psychiatry Research*. 1987;20:13-18.
13. **Khan A**, Cohen S, Chiles J, Stowell M, Hyde T, Robbins M. Therapeutic role of a psychiatric intensive care unit in acute psychosis. *Comprehensive Psychiatry*. 1987;28:264-269.
14. Dunner DL, Myers J, **Khan A**, Avery D, Ishiki D, Pyke R. Adinazolam - a new antidepressant: findings of a placebo controlled, double-blind study in outpatients with major depression. *Journal of Clinical Psychopharmacology*. 1987;7:170-172.
15. **Khan A**, Cohen S, Stowell M, Capwell R, Avery D, Dunner DL. Treatment options in severe psychotic depression. *Convulsive Therapy*. 1987;3(2):93-99.
16. Cohen S, **Khan A**, Johnson S. Pharmacological management of manic psychosis in an unlocked setting. *Journal of Clinical Psychopharmacology*. 1987;7:261-264.
17. Cohen S, **Khan A**. Adjunctive benzodiazepines in acute schizophrenia. *Neuropsychobiology*. 1987;18:9-12.
18. Cohen S, **Khan A**. Respiratory distress with use of lorazepam in mania. *Journal of Clinical Psychopharmacology*. 1987;7:199-200.
19. Geiduschek J, Cohen S, **Khan A**, Cullen BF. Repeated anesthesia for a patient with neuroleptic malignant syndrome. *Anesthesiology*. 68: 134-137, 1988.
20. Scher M, Hartford J, **Khan A**, Gentry R, Wilson L. Comparison of two formats for a psychiatry clerkship. *Journal of Medical Education*. 1988;63:140-143.
21. Solan W, **Khan A**, Avery D, Cohen S. Psychotic and nonpsychotic depression: comparison of response to ECT. *Journal of Clinical Psychiatry*. 1988;49(3):97-99.
22. Cohen S, **Khan A**, Clark A, Goldner M, Dunner DL. Hospitalization effect in acute mania. *General Hospital Psychiatry*. 1988;10:138-141.
23. Cohen S, **Khan A**, Robison J. Significance of mixed features in acute mania. *Comprehensive Psychiatry*. 1988;29:421-426.
24. **Khan A**, Johnson F, Avery D, Cohen S, Scherzo B, Dunner DL. DST results in nonpsychotic depressed outpatients. *American Journal of Psychiatry*. 1988;145:1153-1156.
25. **Khan A**, Cohen S, Dager S, Avery D, Dunner DL. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. *Journal of Affective Disorders*. 1989;17:33-38.
26. Cohen S, **Khan A**, Cox G. Demographic and clinical features predictive of recovery in acute mania. *The Journal of Nervous and Mental Disease*. 1989;177:638-642.
27. **Khan A**, McMurray JS, McCreery JM, Hunt H. Carbamazepine and SIADH. *American Journal of Psychiatry*. 1989;146:1639.
28. Vitiello MV, Prinz PN, Avery DH, Williams DE, Ries RK, Bokan JA, **Khan A**. Sleep is undisturbed in elderly, depressed individuals who have not sought health care. *Biological Psychiatry*. 1990;27:431-440.
29. Scher M, Briggs T, **Khan A**, Cohen S. Patient satisfaction with care received in teaching settings. *Academic Psychiatry*. 1990;12:21-26.
30. Cohen S, **Khan A**. The antipsychotic effect of milieu in the acute treatment of schizophrenia. *General Hospital Psychiatry*. 1990;12:248-251.

31. Healey W, **Khan A**, Noonan C. Major depression with psychosis (MD-P): demographic, phenomenological, and outcome characteristics in one hospitalized population. *Journal of Nervous and Mental Disease*. 1990;178:722-723.
32. Dager SR, **Khan A**, Cowley D, Avery DH, Elder J, Roy-Byrne P, Dunner DL. Characteristics of placebo response during long-term treatment of panic disorder. *Psychopharmacology Bulletin*. 1990;26:273-278.
33. Avery DH, **Khan A**, Dager SR, Cox G, Dunner DL. Bright light treatment of winter depression: morning versus evening light. *Acta Psychiatrica Scandinavica*. 1990;82:335-338.
34. Avery DH, **Khan A**, Dager SR, Cohen S, Cox GB, Dunner DL. Morning or evening bright light treatment of winter depression? The significance of hypersomnia. *Biological Psychiatry*. 1991;29:117-126.
35. Avery D, **Khan A**, Dager S, Cohen S, Cox G, Dunner DL. Is morning light exposure superior to evening light in treating seasonal affective disorder? *Psychopharmacology Bulletin*. 1990;26:521-524.
36. **Khan A**, Dager S, Cohen S, Avery D, Scherzo B, Dunner DL. The chronicity of depressive episode in relation to antidepressant-placebo response. *Neuropsychopharmacology*. 1991;4:125-130.
37. Cohen S, **Khan A**, Zheng Y, Chiles J. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population. *Acta Psychiatrica Scandinavica*. 1991;83:234-237.
38. **Khan A**, Fabre L, Rudolph R. Venlafaxine in depressed outpatients. *Psychopharmacology Bulletin*. 1991;27:141-144.
39. **Khan A**, Brown WA. Who should receive antidepressants: suggestions from placebo treatment. *Psychopharmacology Bulletin*. 1991;27:271-274.
40. **Khan A**, Noonan C, Healey W. Is a single tricyclic antidepressant trial an active treatment for psychotic depression? *Progress in Neuropsychopharmacology and Biological Psychiatry*. 1991;15:765-770.
41. **Khan A**, Shim H, Mirolo MH, Horita A, Douglas R, Tucker GJ. TRH effects on arousal, locomotor activity and spontaneous alternation in ECS post-ictal state. *Psychopharmacology*. 1992;106:570-571.
42. Davis JM, Janicak PG, **Khan A**. Neuroleptic Malignant Syndrome. In: Dunner DL, ed., *Current Psychiatric Therapy*, WB Saunders, Philadelphia, Pennsylvania, 170-175, 1992.
43. Goren A, Swindell C, **Khan A**. Expressive language characteristics of schizophrenic subjects with different medication histories. *Journal of Neurolinguistics*. 1992;7:67-90.
44. **Khan A**, Mirolo HA, Mirolo MH. Depression in the elderly: A treatable disorder. *Geriatrics*. 1993;48(suppl 1):14-17.
45. **Khan A**, Mirolo MH, Claypoole K, Hughes D. Low dose TRH effects in cognitively impaired alcoholics. *Alcoholism: Clinical and Experimental Research*. 1993;17:791-796.
46. **Khan A**, Mirolo MH, Hughes D, Bierut L. Electroconvulsive Therapy. *Psychiatric Clinics of North America*. 1993;16:497-513.

47. **Khan A**, Mirolo MH, Mirolo HA, Miller S. Can ECT-induced cognitive effects be altered pharmacologically? *Progress in Neuropsychopharmacology and Biological Psychiatry*. 1993;17:861-874.
48. **Khan A**, Mirolo MH, Lai H, Claypoole K, Bierut L, Malik R, Bhang J. ECT and TRH: Cholinergic Involvement in a Cognitive Deficit State. *Psychopharmacology Bulletin*. 1993;29:345-352.
49. **Khan A**, Lai H, Ukai Y, Mirolo MH. NS-3, a TRH-Analog, Reverses Repeated ECS Induced Deficits in Water-Maze Performance in the Rat. *Pharmacology, Biochemistry and Behavior*. 1994;47:477-481.
50. Brown WA and **Khan A**. Which Depressed Patients Should Receive Antidepressants? *CNS Drugs*. 1994;1:341-347.
51. Rosenfarb IS, Becker J, **Khan A**. Perceptions of parental and peer attachments by women with mood disorders. *Journal of Abnormal Psychology*. 1994;103:637-644.
52. **Khan A**, Mirolo MH, Claypoole K, Bhang J, Cox G, Horita A, Tucker GJ. Effects of low-dose TRH in the ECT post-ictal state. *American Journal of Psychiatry*. 1994;151:1694-1696.
53. Rosenfarb IS, Becker J, **Khan A**, Mintz J. Dependency, self-criticism, and perceptions of socialization experiences. *Journal of Abnormal Psychology*. 1994;103:669-675.
54. **Khan A**, Lai H, Nishimura Y, Mirolo MH, Singh NP. Effect of ECS on DNA single-strand breaks in rat brain cells. *Convulsive Therapy*. 1995;11:114-121.
55. Singh NP and **Khan A**. Acetaldehyde: geno- and cytotoxicity in human lymphocytes. *Mutation Research*. 1995;337:9-17.
56. **Khan A**, Rudolph R, Baumel B, Ferguson J, Ryan PJ, Shrivatsava R. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. *Psychopharmacology Bulletin* 1995;31:753-758.
57. Singh NP, Graham, MM, Singh V, **Khan A**. Induction of DNA single-strand breaks in human lymphocytes by low doses of gamma rays. *International Journal of Radiation Biology*. 1995;68:563-569.
58. Singh NP, Lai H, **Khan A**. Ethanol-induced single-strand DNA breaks in rat brain cells. *Mutation Research*. 1995;345:191-196.
59. **Khan A**. Overall safety profile of venlafaxine: a commentary. *Journal of Clinical Psychopharmacology*. 1996;16(suppl 2):59S-61S.
60. Chandos B, **Khan A**, Lai H, Lin JC. In: Ueno E, ed. The application of electromagnetic energy to the treatment of neurological and psychiatric diseases. *Biological effects of magnetic and electromagnetic fields*, Plenum Press, NY. 1996, pp.161-169.
61. **Khan A**. Letter to the Editor (Antidepressant Discontinuation Syndrome), *Psychiatric Annals*. 1997;27:259.
62. Lehman AK, Ellis B, Becker J, Rosenfarb I, Devine R, **Khan A**, Reichler R. Personality and depression: a validation study of the Depressive Experiences Questionnaire. *Journal of Personality Assessment*. 1997;68(1):197-210.
63. **Khan A**, Upton, GV, Rudolph R, Entsuah R, Leventer SM and venlafaxine investigator study group. The use of venlafaxine in the treatment of major depression and major

- depression associated with anxiety: A dose-response study. *Journal of Clinical Psychopharmacology*. 1998;18(1):19-25.
64. Rosenfarb IS, Becker J, **Khan A**, Mintz J. Dependency and self-criticism in bipolar and unipolar depressed women. *British Journal of Clinical Psychology*. 1998;37:409-414.
 65. **Khan A**. Treating Depression. *Psychiatric Annals*. 1999;29(3):123-124.
 66. **Khan A**, Warner H, Brown, WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database. *Archives of General Psychiatry*. 2000;57:311-317.
Invited Commentaries by Drs. Leber, Michels, Quitkin, Klein, Hirschfeld, Chmura Kramer, Leon. Archives of General Psychiatry. 2000;57:319-330.
Cited in New York Times. Erica Goode. More fuel for debate on Prozac. OL.CXLIX, No. 51; 369, Tuesday, April 25, 2000
Cited in Science. Martin Enserink. Are placebo-controlled drug trials ethical? Science 2000;288:5465,p. 416.
Cited in WebMD. Amy Rothman Schonfeld. Analysis of FDA data indicates placebo-treated patients not at increased risk for suicide compared with active controls-experts debate the role of placebo-controlled trials. April 17, 2000.
Cited in Science News. Bruce Bower. Placebos for depression attract scrutiny, 157: April 29, 2000, p.278.
 67. Cohen S, Glazewski R, Khan S, **Khan A**. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. *Journal of Clinical Psychiatry*. 2001;62:114-116.
 68. **Khan A**, Brown WA. The placebo enigma in antidepressant clinical trials. *Invited Guest Editorial. Journal of Clinical Psychopharmacology*. 2001;21:123-125.
 69. **Khan A**, Khan S, Leventhal R, Brown W. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. *International Journal of Neuropsychopharmacology*. 2001;4:113-118.
 70. **Khan A**, Khan S, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA database. *American Journal of Psychiatry*. 2001;158:1449-1454.
 71. **Khan A**, Leventhal RM, Khan S, Brown WA. Severity of depression and response to antidepressants and placebo: An analysis of the FDA database. *Journal of Clinical Psychopharmacology*. 2002;22:40-45.
 72. **Khan A**, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. *Journal of Affective Disorders*. 2002;68:183-190.
 73. **Khan A**, Khan S, Leventhal RM, Krishnan R, Gorman J. An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. *Biological Psychiatry*. 2002;52:62-67.
 74. **Khan A**, Leventhal RM. Medical aspects of capital punishment executions. *Journal of Forensic Science*. 2002;47:847-851.

75. **Khan A**, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? *International Journal of Neuropsychopharmacology*. 2002;5:193-197.
76. **Khan A**, Khan SR, Shankles EB, Polissar NL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. *International Clinical Psychopharmacology* 2002;17:281-285.
77. Cohen S, Fitzgerald B, Okos A, Khan S, **Khan A**. Weight, lipid, glucose and behavioral measures with ziprasidone treatment in a population with mental retardation. *Journal of Clinical Psychiatry*. 2003;64:60-62.
78. **Khan A**, Khan S. Placebo in mood disorders: the tail that wags the dog. *Current Opinion in Psychiatry*. 2003;16:35-39.
79. **Khan A**, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval reports. *Neuropsychopharmacology*. 2003;28:552-557.
80. **Khan A**, Detke M, Khan S, Mallenkrodt C. Placebo response and antidepressant clinical trial outcome. *Journal of Nervous and Mental Disease*. 2003;19:211-218.
81. **Khan A**, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: Analysis of FDA reports. *American Journal of Psychiatry*. 2003;160:790-792.
82. Storosum J, van Zweiten B, Wohlfarth T, de Haan L, **Khan A**, van der Brink W. Suicide risk in placebo versus active treatment in placebo-controlled trials for schizophrenia. *Archives of General Psychiatry*. 2003;60:365-368.
83. Cohen SA, Fitzgerald BJ, Khan S, **Khan A**. The effect of a switch to Ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment. *Journal of Clinical Psychiatry*. 2004;65:110-113.
84. Robinson D, **Khan A**. Dosing strategies for antidepressant clinical trials: A commentary (Editorial). *Journal of Clinical Psychopharmacology*. 2004;24:1-3.
85. **Khan A**, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg Depression rating Scale, the Hamilton Depression rating Scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: A replication analysis. *International Clinical Psychopharmacology*. 2004;19:157-160.
86. Rickels K, Mangano R, **Khan A**. A double-blind, placebo-controlled study of a flexible dose of Venlafaxine ER in adult outpatients with generalized social anxiety disorder. *Journal of Clinical Psychopharmacology*. 2004;24:488-496.
87. **Khan A**, Kolts RL, Thase ME, Krishnan KR, Brown WA. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. *American Journal of Psychiatry*. 2004;160:2045-2049.
88. **Khan A**, Ginsberg LD, Asnis GM, Goodwin FK, Davis KH, Kishnan AA. Effect of Lamotrigine on cognitive complaints in patients with bipolar I disorder. *Journal of Clinical Psychiatry*. 2004;65:1483-1490.

89. Labellarte M, Biederman J, Emslie G, Ferguson J, **Khan A**, Ruckle J, Sallee R, Riddle M. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry*. 2004;43:1497–1505.
90. **Khan A**, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials. *Journal of Psychiatric Research*. 2005;39:145-150.
91. **Khan A**, Kolts RL, Rapaport MH, Krishan KR, Brodhead AE, Brown WA. Magnitude of placebo response and drug placebo differences across psychiatric disorders. *Psychological Medicine*. 2005;35:743-749.
92. **Khan A**, Schwartz K. Study designs and outcome in antidepressant clinical trials. *Essential Psychopharmacology*. 2005;6:221 – 226.
93. **Khan A**, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response among outpatients participating in antidepressant clinical trials. *Journal of Clinical Psychopharmacology*. 2005;25:318-324.
Cited in Consumer Reports on Health. Drug Safety: His and Hers. December 2005.
94. **Khan A**, Schwartz K. Design features that affect psychopharmacology trials. *Letters in Drug Design & Discovery*. 2005;2:546-550.
95. DeBattista C, Belanoff J, Glass S, **Khan A**, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone vs Placebo in the treatment of psychosis in patients with psychotic major depression. *Biological Psychiatry*. 2006;60:1343-9.
96. **Khan A**, Brodhead AE. Fixed and flexible dosing strategies among antidepressant clinical trials. *Salud Mental*. 2005;9:4-5.
97. **Khan A**, Kolts RL, Brodhead AE, Krishnan KR, Brown WA. Suicide risk analysis among patients assigned to psychotropics and placebo. *Psychopharmacology Bulletin*. 2006;39: 6-14.
98. **Khan A**, Stern C. Design features, patient characteristics associated with antidepressant clinical trial outcome. *Sociedad Iberoamericana de Informacion Cientifica*. Nov. 2006.
99. **Khan A**, Schwartz KA, Kolts RL, Brown W. BMI, sex, and antidepressant response. *Journal of Affective Disorders*. 2006;99(1-3):101-106.
100. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, **Khan A**, Calabrese J, BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). *Journal of Clinical Psychopharmacology*. 2006;26:600-609.
101. Thase ME, Shelton RC, **Khan A**. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance. *Journal of Clinical Psychopharmacology*. 2006;26:250-258.
102. **Khan A**, Schwartz K, Kolts RL, Ridgway D, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. *Biological Psychiatry*. 2007; 62:65-71.
103. **Khan A**, Schwartz K. Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA Summary Basis of Approval reports. *Annals of Clinical Psychiatry*. 2007;19:1-6.

104. Ferguson JM, **Khan A**, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. *Journal of Clinical Psychiatry*. 2007;68:58-68.
105. Alper K, Schwartz KA, Kolts RL, **Khan A**. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. *Biological Psychiatry*. 2007;62:345-54.
106. **Khan A**, Schwartz K, Kolts RL, Redding N, Brown, WA. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. *Neuropsychopharmacology*. 2007;32:2422-30.
107. **Khan A**, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. *Clinical Drug Investigation*. 2007;27:481-492.
108. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, **Khan A**. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *Journal of Clinical Psychiatry*. 2007;68:843-853.
109. **Khan A**, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson D. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. *Journal of Clinical Psychiatry*. 2007;68:1828-1833.
110. Ridgway D, **Khan A**, Ridgway G, Cierpial MA, Linebery CG. Subject numbers and placebo outcome variability in clinical trials of new CNS medications. *Drug Information Journal*. 2007;41:701-709.
111. Thase ME, Jonas A, **Khan A**, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus N, Owen R. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of two randomized, placebo-controlled studies. *Journal of Clinical Psychopharmacology*. 2008;28:13-20.
112. **Khan A**, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. *Journal of Psychiatric Research*. 2008;42:791-796.
113. Nelson JC, Thase ME, **Khan A**. Are antidepressants effective? What's a Clinician to think? *J Clinical Psychiatry*. 2008;69:1014-1015.
114. **Khan A**, Khan S. Placebo response in depression: a perspective for clinical practice. *Psychopharmacology Bulletin*. 2008;41(3):91-98.
115. **Khan A**. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. *Expert Reviews of Neurotherapeutics*. 2008;8:1435-1447.
116. Gelenberg A, Thase M, Meyer R, Goodwin F, Katz M, Kraemer H, Potter W, Shelton R, Fava M, **Khan A** et al. The history and current state of antidepressant clinical trial design: a call to action for proof – of – concept studies. *Journal of Clinical Psychiatry*. 2008;69:1513- 1528.
117. **Khan A**, Bhat A. Is the problem of a high placebo response unique to antidepressant trials? *Journal of Clinical Psychiatry*. 2008;69:1979-1980.
118. **Khan A**. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. *Expert Opinion on Investigational Drugs*. 2009;18:1-12.

119. Hale M, **Khan A**, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients chronic low back pain. *Current Medical Research and Opinion*. 2010;26:1505-1518.
120. **Khan A**, Bomminayuni EP, Bhat A, Faucett J, Brown W. Are the colors and shapes of current psychotropics designed to enhance the placebo response? *Psychopharmacology*. 2010;211:113-122.
121. **Khan A**, Bhat A, Kolts R, Thase M, Brown W. Why has the antidepressant – placebo difference in antidepressant clinical trials diminished over the past three decades? *CNS Neuroscience & Therapeutics*. 2010;16:217-226.
122. Schwartz JRL, **Khan A**, McCall V, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month open-label study with an extension period. *Journal of Clinical Sleep Medicine*. 2010;6:450-457.
123. **Khan A**, Bhat A, Faucett J, Kolts R, Brown W. Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. *Psychopharmacology*. 2011;214:961-965.
124. Stein MB, Ravindran LN, Simon NM, **Khan A**, Brawman-Mintzer O, Lydiard RB, Pollack MH. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. *Journal of Clinical Psychiatry*. 2010;71:627-631.
125. Marcus R, **Khan A**, Rollin L, Morris B, Timko K, Carson W, Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar 1 disorder with an inadequate response to lithium or valproate monotherapy: A multi-center, double-blind, randomized study. *Bipolar Disorders*. 2011;13:133-144.
126. Weisler RH, **Khan A**, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Quynh-Van Tran, Berman RM, Carlson BH. Analysis of suicidality in pooled data from two double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. *Journal of Clinical Psychiatry*. 2011;72:548-555.
127. **Khan A**, Cutler AJ, Kajdasz D, Athanasiou M, Robinson DS, Whalen H, Reed CR. A randomized, double-blind, placebo controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of Major Depressive Disorder. *Journal of Clinical Psychiatry*. 2011; 72:441-447.
128. **Khan A**, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. *Journal of Clinical Psychopharmacology*. 2011;31:418-428.
129. **Khan A**, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R. Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: Role of lithium levels. *Journal of Psychiatric Research*. 2011;45:1489-1496.
130. Webster LR, Michna E, **Khan A**, Israel RJ, Manley A, Zhang H, Maller E, Tzanis E. The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with nonmalignant pain. *Journal of Pain*. 2011;12:70-73.

131. Schilling J, Khan SR, **Khan A**. Outcome measures and serious asthma exacerbation in clinical trials of asthma controller medications. *Annals of Allergy, Asthma & Immunology*, 2012; 108:448-453.
132. **Khan A**, Faucett J, Emslie G, Brown W. Efficacy and safety of antimanic agents in children and adults. *Israel Journal of Psychiatry*, 2012; 49:122-127.
133. **Khan A**, Faucett J, Lichtenberg P, Kirsch I, Brown WA. (2012) A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression. *PLoS ONE* 7(7): e41778. doi:10.1371/journal.pone.0041778.
134. Hale ME, Nalamachu SR, **Khan A**, Kutch M. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone ER in opioid-tolerant patients with chronic low back pain. *Journal of Pain Research*, 2013;6:319-329.
135. **Khan A**, Faucett J, Morrison S, Brown WA. Comparative Mortality Risk in Adult Patients with Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, and Attention-Deficit/Hyperactivity Disorder Participating in Psychopharmacology Clinical Trials. *JAMA Psychiatry*, 2013;70:1071-1099.
136. **Khan A**, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S. Extended release quetiapine fumarate (Quetiapine XR) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate response: A randomized, double-blind study. *Annals of Clinical Psychiatry*, 2013;25(4):E7-E22.
137. **Khan A**, Sambunaris A, Edwards J, Ghori R, Ruth A, Robinson DS. Vilazodone in the treatment of major depressive disorder: Broad efficacy across symptoms and depression severity. *International Clinical Psychopharmacology*, 2014;29(2):86-92.
138. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, **Khan A**. Levomilnacipran ER 40 mg and 80 mg in Major Depressive Disorder: A Phase III, Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Study. *Journal of Psychiatry and Neuroscience*, 2014;39:40-49.
139. **Khan A**, Faucett J, Brown W. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. *Journal of Psychiatric Research*, 2014;51:88-92.
140. **Khan A**, Ninan PT, Ramey T, Messig M, Buckley G, Musgnung J. Abrupt discontinuation compared with a 1-week tapering regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg. *Journal of Clinical Psychopharmacology*, 2014;34:303-306.
141. **Khan A**, Faucett J, Brown W. Magnitude of Change with Antidepressants and Placebo in Antidepressant Clinical Trials Using Structured, Taped and Appraised Rater Interviews Compared to Traditional Semi-Structured Interviews. *Psychopharmacology*, 2014;231:4301-4307.
142. DelBello MP, Hochadel TJ, Portland KB, Katic A, **Khan A**, Emslie G. A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents. *Journal of Child and Adolescent Pharmacology*, 2014;24:311-317.
143. **Khan A**, Faucett J, Brown W. Response to Lipsitz et al. *Journal of Psychiatric Research*, 2014;57:180-181.

144. Nalamachu S, Hale M, **Khan A**. Hydromorphone extended-release for Neuropathic and Non-neuropathic/Nociceptive Chronic Low Back Pain: A Post-Hoc Analysis of Data from a Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. *Journal of Opioid Management*, 2014;10:311-322.
145. **Khan A**, Faucett J, Brown W. Reply to Millman and Opler. *Journal of Psychiatric Research*. 2015;61:243-4.
146. Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, **Khan A**. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. *J Psychiatry Neurosci*, 2014;39:40-49.
147. Mathews M, Gommoll C, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. *International Clinical Psychopharmacology*, 2015;30:67-74.
148. Bhat A, Chowdayya R, Selvam S, **Khan A**, Kolts R, Srinivasan K. Maternal prenatal psychological distress and temperament in 1-4 month old infants – A study in a non-western population. *Infant Behavior and Development*, 2015:35-41.
149. **Khan A**, Brown W. Antidepressants versus placebo in major depression: An overview. *World Psychiatry*, 2015;14:294-300.
150. Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, **Khan A**, Weisler R, Nelson C, Shelton R, Thase ME, Lane R. Assessment of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression: results from two randomized, double-blind studies. *Journal of Clinical Psychopharmacology*, 2015;35:454-459.
151. **Khan A**, Faucett J, Brown WA. Mortality risk with mirtazapine and estimating suicide risk. *JAMA Psychiatry*, 2015;72:9.
152. **Khan A**, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post hoc analyses of anxiety measures in adult patients with generalized anxiety disorder treated with vilazodone. *The Primary Care Companion for CNS Disorders*, 2016;18: doi:10.4088/PCC.15m01904.
153. Thase M, Gommoll C, Chen C, Kramer K, **Khan A**. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. *CNS Spectrums*, 2017;22(6):475-483.
154. Sanacora G, Johnson M, **Khan A**, Atkinsons S, Riesenbergr R, Schronen J, Burke MA, Zajecka J, Barra L, Su H-L, Posener JA, Bui K, Quirk M, Piser T, Matthew S, Pathak S. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. *Neuropsychopharmacology*, Nov 2016. doi: 10.1038/npp.2016.224
155. **Khan A**, Fahl Mar K, Faucett J, Khan Shilling S, Brown WA. Has the rising placebo response impacted antidepressant clinical trial outcomes? Data from the Food and Drug Administration 1987-2013. *World Psychiatry*, 2017;16(2):181-192.
156. Webster LR, Michna E, **Khan A**, Israel R, Harper JR. Long-term safety and efficacy of subcutaneous Methylnaltrexone in patients with opioid-induced constipation and chronic noncancer pain: A phase 3, open-label trial. *Pain Medicine*, 2017;18(8):1496-1504.

157. **Khan A**, Fahl Mar K, Brown WA. Does the increasing magnitude of placebo response affect outcome of adult and pediatric ADHD clinical trials? *Journal of Psychiatric Research*, 2017;94:202-207.
158. **Khan A**, Fahl Mar K, Schilling J, Brown WA. Magnitude and pattern of placebo response in clinical trials of antiepileptic medications: Data from the Food and Drug Administration 1996 - 2016. *Contemporary Clinical Trials*, 2017;64:95-100.
159. **Khan A**, Fahl Mar K, Brown WA. The impact of underpowered studies on clinical trial results. *American Journal of Psychiatry*, 2018;175(2):188.
160. **Khan A**, Fahl Mar K, Schilling J, Brown WA. Magnitude and pattern of placebo response in clinical trials of oral antihyperglycemic agents: Data from the Food and Drug Administration 1999 – 2015. *Diabetes Care*, 2018;41(5):994-1000.
161. **Khan A**, Fahl Mar K, Schilling J, Brown WA. Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of Food and Drug Administration data 1990-2016. *PLoS One*, Feb 28, 2018; <https://doi.org/10.1371/journal.pone.0193043>
162. **Khan A**, Fahl Mar K, Gokul S, Brown WA. Decreased suicide rates in recent antidepressant clinical trials. *Psychopharmacology*, 2018;235(5):1455-1462.
163. **Khan A**, Fahl Mar K, Brown WA. The conundrum of depression clinical trials: One size does not fit all. *International Clinical Psychopharmacology*, 2018;33(5):239-248.
164. **Khan A**, Fahl Mar K, Gokul S, Brown WA. Mortality during clinical trials in patients with diabetes, hypertension, depression, and schizophrenia. *World Journal of Biological Psychiatry*, DOI:10.1080/15622975.2018.1514465.

Current Projects

Khan A, Fahl Mar K, Brown WA. The rising placebo response and its impact on trial outcomes among medical and neuropsychiatric conditions. *Under Review*

Khan A, Fahl Mar K, Brown WA. The impact of a rising placebo response on drug response and the theory of additivity in clinical trials of neuropsychiatric and medical conditions. *In Development*

Abstracts, Book Reviews, and Other Publications:

1. **Khan A**, Johnson GA and Becker JT. Catecholamine turnover with ECT. 14th Annual Meeting of Society for Neuroscience (Abstract, p. 289, Part I), 1984.
2. Becker JT, **Khan A**, Reddy AS. Hypothalamic amnesia in man. 14th Annual Meeting of Society for Neuroscience (Abstract, p. 385, Part I), 1984.
3. **Khan A**, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner DL. Platelet MAO-B activity in anxiety and depression. IV Congress in Biological Psychiatry (Abstract p. 90), 1985.

4. Dager S, **Khan A**, Comess K, Raisys V, Dunner DL. MHPG/creatinine, MAO-B activity, autonomic arousal and MVP in anxious patients. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 106), 1986.
5. **Khan A**, Cohen S, Chiles J, Dunner DL. Therapeutic role of a psychiatric care unit in acute psychosis. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 37), 1987.
6. **Khan A**, Hyde T and Dunner DL. Treatment response to placebo and IMI/DMI in outpatients with major depression. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 243), 1987.
7. **Khan A**, Cohen S, Avery D, Dunner DL. Treatment options in psychotic depression. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 242), 1987.
8. Avery D, **Khan A**, Dager S, Dunner DL. Temperature rhythm phase-typing of seasonal affective disorder and response to Am and PM bright light. Annual Meeting of the Sleep Research Society (Abstract), 1987.
9. Nelson WH, **Khan A**. Age effects on the dexamethasone suppression test in unipolar major depression. *Neuroendocrinology letters*; 9:181, 1987.
10. **Khan A**, Dunner DL. Clinical predictors of placebo response in depressed outpatients. Panel presentation at 26th Annual Meeting of American College of Neuropsychopharmacology (Abstract, p. 58), 1987.
11. Avery D, **Khan A**, Cohen S. Bright light treatment of SAD: AM vs PM light. Symposium at World Psychiatric Association Washington, DC (Abstract), 1988.
12. **Khan A**. Acute treatment of psychotic depression. *Clinical Advances in the Treatment of Psychiatric Disorders* 2; 4: 4, 1988.
13. **Khan A**, Dunner DL. Study group participant on placebo response at the 27th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 56), 1988.
14. Cohen S, **Khan A**. Hospitalization effect on acute exacerbation of schizophrenia. *Schizophrenia Research* 2: 220, 1989.
15. **Khan A**, Dager S, Dunner DL. Clinical and demographic features related to placebo and antidepressant response. *Biological Psychiatry* 25:79-80A, 1989, (Suppl).
16. **Khan A**. Book Review on "Electroconvulsive Therapy" by Richard Abrams, MD, 1988. *Journal of Nervous and Mental Disease* 177:501-502, 1989.
17. **Khan A**. Study group participant on placebo response in depression at the 28th Annual Meeting of the American College of Neuropsychopharmacology, (Brown and Dunner, Abstract, p. 44), 1989.
18. **Khan A**, Dager S, Cohen S, Avery D, Dunner DL. When is the onset of response to antidepressant? 28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 198), 1989.
19. Dager S, **Khan A**, Cowley DC, Avery DH, Elder J, Roy-Byrne P, Dunner DL. Clinical characteristics of placebo response among panic patients. 28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 183), 1989.
20. Cohen S, **Khan A**, Cox G. Demographic and clinical features predictive of recovery in acute mania. *Psychiatry Digest* 6:23-25, 1990.
21. **Khan A** and Brown WA. Who should receive antidepressants: suggestions from placebo treatment. 29th Annual Meeting of the American College of Neuropsychopharmacology,

- (Abstract, p. 138) December, 1990.
22. **Khan A**, Mirolo MH, Horita A, Lampe T, Tucker GJ. TRH in ECT/ECS post-ictal state. 30th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 233), 1991.
 23. **Khan A**, Lai H, Mirolo MH, Ukai Y. TRH and ECT: Cholinergic involvement in cognitive deficit state. 31st Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 106) 1992.
 24. **Khan A**. Book review on "Electroconvulsive Therapy" by Richard Abrams, Second Edition. *Journal of Nervous and Mental Disease*; 181:592, 1993.
 25. **Khan A**, Steiert J, Githens S. Effective collaboration with managed care. 146th Annual Meeting of the American Psychiatric Association, (Issue Workshop #12, Abstract p. 303-304), 1993.
 26. **Khan A**, Mirolo MH, Claypoole K, Lai H, Tucker G. Low-dose TRH effects in ECT post-ictal state. Annual Meeting of the Society of Biological Psychiatry (Abstract, p. 654), 1994.
 27. **Khan A**, Lai H, Nishimura Y, Mirolo MH, Singh NP. ECS effects on neuronal DNA strand breaks. Annual Meeting of the Society of Biological Psychiatry (Abstract, p. 664), 1994.
 28. Singh NP, Malik S, Kenny MA, Lai H, **Khan A**. Acetaldehyde induced DNA single strand breaks in human lymphocytes. Annual Meeting of the Society of Biological Psychiatry (Abstract, p. 708), 1994.
 29. **Khan A**, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivatsava R, Mirolo MH. Venlafaxine in depressed geriatric outpatients: an open label study. XIXth CINP Congress (Abstract, p. 163S), 1994.
 30. Ferguson J, **Khan A**, Kucharik R, Leventer S, and Cucci C. A placebo-controlled comparative study of the effects on blood pressure and antidepressant efficacy of venlafaxine and imipramine. XIXth CINP Congress (Abstract, p. 165S), 1994.
 31. **Khan A**, and Montgomery N. Seizure Inhibition Syndrome. Annual Meeting of the Association for convulsive Therapy (Abstract in Convulsive Therapy, p. 70), 1995.
 32. **Khan A**. Overall safety profile of venlafaxine: a commentary. An invited abstract for Psychiatry Digest, February (Abstract p. 27-28), 1997.
 33. **Khan A**. Panel Participant: IMGs and ABPN Performance, APA Annual meeting (p. 36) 1997.
 34. **Khan A**, Warner H and Brown WA. Placebo in Antidepressant Clinical trials: Efficacy and safety. 36th Annual Meeting of the American College of Neuropsychopharmacology (Abstract p.138). December, 1997.
 35. **Khan A**, (Chair) Brown WA (Moderator) and Quitkin F (ACNP Invitee). Are placebo controls ethical in antidepressant clinical trials? Study Group at the 37th Annual Meeting of the American College of Neuropsychopharmacology, 1998
 36. Cookson J, **Khan A**, Asnis P et al. Profile of antidepressant activity of lamotrigine (Lamictal) in Bipolar and Unipolar Depression: Results from double-blind, placebo-controlled studies. 12th Annual meeting of the European College of Neuropsychopharmacology (Abstract), September 1999.
 37. Efficacy of lamotrigine in bipolar and unipolar depression: results from double-blind,

- placebo-controlled studies. Asnis G, Beaman M, Bowden C, Calabrese, De Veugh-Geiss, Evoniuk G, Huffman R and **Khan A**. 38th Annual Meeting of the American College of Neuropsychopharmacology, December 1999 (Abstract p. 162).
38. **Khan A** and Khan S. Are placebo controls ethical in antidepressant clinical trials? Invited Article for *Psychiatric Times*, XVII: 4 – 29, April 2000.
 39. **Khan A**, Warner H, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. *Archives of General Psychiatry*, April, 2000, vol. 57, © American Medical Association. pp 311-317 (see also pages 319, 321, 323, 325, 327 & 329)
 40. Huffman R, Ascher J, **Khan A**, and Calabrese J. Evaluation of efficacy and safety of lamotrigine for the long-term treatment of bipolar depression. New Clinical Drug Evaluation Unit (NCDEU), poster #51, 2000.
 41. Earl N, Greene P, Ascher J, Fouche N, Chang C, Evoniuk G, Swann A, Pope S, Ketter T, McElroy S, Post R, Zajecka J, Altshuler L, Apter J, Wets S, Risch C, **Khan A**. Mood stabilization with lamotrigine in rapid cycling bipolar disorder. European College of Neuropsychopharmacology (ECNP) Annual Meeting, Munich, September, 2000.
 42. Labetelle M, Zimbrun T, Brennan J, Biederman J, Connor J, Emslie G, Ferguson J, **Khan A**, Ruckle J, Sallee R, Riddle M. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. Child Neuropsychiatry Conference (Pisa), poster, May, 2000.
 43. **Khan A**, Khan S, Leventhal R, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA database. 39th Annual meeting of the American College of Neuropsychopharmacology (Abstract #178), 2000.
 44. Suppes T, Altshuler L, Apter J, Bowden C, Calabrese J, Ginsberg L, Goldberg J, Gyulai L, **Khan A**, McElroy S, Rapaport M, Risch S, Scabs G, Swann A, West S, Zajecka J, Ascher J, Barrows C, Earl N, Greene P. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: a double-blind placebo-controlled study. 39th Annual meeting of the American College of Neuropsychopharmacology (Abstract #99), 2000.
 45. **Khan A**, Khan SR, Brown WA. Do psychotropics reduce suicide risk? 40th Annual Meeting of the American College of Neuropsychopharmacology (Abstract #159, p. 186), 2001
 46. Pollock MH, Feltner, DE, Rickels K, Lydiard RB, Zimbroff DL, Bieski RJ, **Khan A**, Goodrich J, Brock JD, Pande AC. A placebo-controlled, double-blind study of pregabalin treatment of generalized anxiety disorder. 40th Annual Meeting of the American College of Neuropsychopharmacology (Abstract #46, p. 337), 2001.
 47. Bowden C, Ghaemi N, Gyulai L, Huey L, **Khan A**, Montgomery P, Ascher, J. Lamotrigine delays mood episodes in recently depressed bipolar I patients. Annual meeting of the American Psychiatric Association, 2002.
 48. **Khan A**, Khan S, Walens G, Giller E. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval reports. 41st Annual Meeting of the American College of Neuropsychopharmacology (poster), 2002.

49. **Khan A**, Khan S, Kolts R, Brown WA. Suicide rate with SSRI antidepressants compared to other antidepressants and placebo. 41st Annual Meeting of the American College of Neuropsychopharmacology (poster), 2002.
50. **Khan A**, Khan S, Kolts R, Brown WA. Research design factors associated with antidepressant clinical trial outcome. New Clinical Drug Evaluation Unit, May 2003.
51. **Khan A**, Kolts R, Brown WA. Research Design Features associated with antidepressant clinical trial outcome. 42nd Annual meeting of the American College of Neuropsychopharmacology, 2003.
52. **Khan A**, Brodhead AE, Kolts RL, Brown WA. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Clinical Global Impressions Rating Scale in antidepressant clinical trials. New Clinical Drug Evaluation Unit, poster #174, June 2004.
53. **Khan A**, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials. New Clinical Drug Evaluation Unit, poster #176, June 2004.
54. **Khan A**, Brodhead AE, Lai H, Singh NP. Commercial potential of toxins, developing toxins for applications in drug discovery and diagnostics. International Society on Toxinology- European Section, 15th European Symposium on Animal, Plant and Microbial Toxins, June 2004.
55. **Khan A**, Schwartz TL. Tiagabine as an efficacious augmentation therapy to selective serotonin reuptake inhibitors in patients with generalized anxiety disorder. 17th European College of Neuropsychopharmacology, October 2004.
56. **Khan A**, Brodhead AE, Kolts RL, Brown WA. Sex differences in SSRI antidepressant response among outpatients participating in antidepressant clinical trials. 43rd Annual meeting of American College of Neuropsychopharmacology, December 2004.
57. **Khan A**, Schwartz KA, Kolts RL, Brodhead AE, Brown WA. Sex differences and BMI in relation to antidepressant clinical trial outcomes. New Clinical Drug Evaluation Unit, June 2005.
58. **Khan A**, Schwartz KA. Clinical trials: 20-year trends and predictors of success. New Clinical Drug Evaluation Unit, June 2005.
59. **Khan A**, Alper K, Schwartz K, Kolts R, Brown W. Seizure risk among patients participating in psychopharmacology clinical trials. Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2005.
60. **Khan A**, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W. Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials. APA Lunch Forum: Hot Topics in Psychopharmacology and Drug Safety. Annual Meeting of the American Psychiatric Association, May 2006.
61. **Khan A**, Farfel GM, Brock JD, Kavousi R, Chatamra K. Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients. Annual Meeting of American Psychiatric Association (poster), May 2006.
62. **Khan A**, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W. Seizure, suicide, and mortality among psychiatric patients based on FDA SBA reports. Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2006.

63. **Khan A**, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W. Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials. Enhancing precision in clinical trials: recruitment, study design, measurement, endpoints. Annual Meeting for New Clinical Drug Evaluation Unit, June 2006.
64. **Khan A**, Schwartz K, Kolts RL, Ridgway D, Redding N, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.
65. Brown WA, Redding N, Kolts RL, **Khan A**. The persistence of the placebo response in antidepressant clinical trials. Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.
66. Cohen SA, Redding N, Petras A, **Khan A**. Clinician weight as a factor in prescribing atypical antipsychotics. Annual Meeting of the American Psychiatric Association (APA), poster NR374, May 2007.
67. **Khan A**, Redding N. Mortality rates in antipsychotic and antidepressant clinical trials: evaluating short and long-term safety for CNS agents. Annual Meeting for New Clinical Drug Evaluation Unit (NCDEU), June 2007
68. Brown WA, Solomon DA, **Khan A**. Book review on “Handbook of Contemporary Neuropharmacology” by Sibley D, Hanin I, Kuhar M, Skolnick P (eds). *JAMA* 298(22): 2682-2683, 2007.
69. **Khan A**, Bhat A. Failed antidepressant trials: causes and solutions. Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2008.
70. **Khan A**, Bhat A, Kolts R, Thase M, & Brown W. Decrease in antidepressant placebo differences over time is associated with changes in research design features. Annual Meeting of the American College of Neuropsychopharmacology (poster), November 2008.
71. **Khan A**, Bhat A, Kolts R. Vilazodone – efficacy and safety evaluation from a single center. Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2009.
72. **Khan A**, Bhat A, Kolts R, Brown W. Does maintaining baseline severity of depressive symptoms over time affect antidepressant – placebo differences? Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2009.
73. **Khan A**, Cutler AJ, Kajdasz D, Athanasiou M, Robinson DS, Whalen H, Reed CR. Efficacy and tolerability of vilazodone, a dual-actin serotonergic antidepressant, in the treatment of patients with major depressive disorder. Annual Meeting of the American Psychiatric Association, poster NR42, May 2010.
74. Owen R, Rollin L, **Khan A**, Sanchez R, Carson W, Morris B, Timko K, Marcus R. Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar I disorder. Annual Meeting of the American Psychiatric Association (presentation), May 2010.
75. **Khan A**, Bhat A, Faucett J, Kolts R, Brown W. Antidepressant-placebo differences over an eleven year period in a sample of patients with high and similar baseline scores. Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2010.

76. Abbar M, Owen R, Rollin L, **Khan A**, Sanchez A, Carson W, Morris B, Timko K, Marcus RN. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of mania in subjects with bipolar 1 disorder. 23rd Meeting of the European College of Neuropsychopharmacology (poster), August, 2010.
77. **Khan A**. *Invited Commentary on: Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population based nested case-control study by Bandrup et al.* Evidence Based Mental Health; 13:90 doi:10.1136/ebmh.13.3.90, 2010.
78. **Khan A**, Faucett J, Brown W, Emslie G. Comparison of Efficacy and Safety Measures Between Pediatric and Adult Clinical Trials for Bipolar Mania Based on Food and Drug Administration Summary Basis of Approval Reports. 49th Annual Meeting for the American College of Neuropsychopharmacology. December, 2010.
79. Abbar M, **Khan A**, Rollin LM, Sanchez R, Carson W, Morris B, Timko K, Marcus RN. Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar 1 disorder. 19th European Congress of *Psychiatry* (poster), Prague, Czeck Republic, March 2011.
80. **Khan A.**, Rutherford B., Sinyor, M., Mischoulon, D., Brown, W. Why do antidepressant trials fail? Symposium Chair and presentation for the 2011 APA Conference in Honolulu, HI. May, 2011.
81. Webster L, Michna E, **Khan A**, Manley A, Zhang H, Tzanis E, Maller E. The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain. Annual Meeting for the American Pain Society (poster). Austin, TX, May 2011.
82. Webster L, Michna E, Khan A, Israel R, Manley A, Zhang H, Maller E, Tzanis E. Subcutaneous methylnaltrexone provides long-term laxation in patients with chronic non-malignant pain and opioid-induced constipation. Annual Meeting for the American Pain Society (poster). Austin, TX, May 2011.
83. **Khan A**, Faucett J, Lichtenberg P, Brown W. Placebo control in antidepressant trials: A misnomer. Annual Meeting for the New Clinical Drug Evaluation Unit (poster), Boca Raton, FL, June 2011. Nominated for Best Poster and Invited for 2011 NCDEU Online CME Poster Presentation.
84. **Khan A**, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R. Changes in suicide risk measures and depressive symptoms with lithium combined with citalopram compared to citalopram with placebo in severely ill and suicidal depressed patients: A randomized, double-blind trial. Annual Meeting for the New Clinical Drug Evaluation Unit (poster), Boca Raton, FL, June 2011.
85. **Khan A**. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar 1 disorder with an inadequate response to lithium or valproate monotherapy: A multi-center, double-blind, randomized study. Podcast for Journal of Bipolar Disorder. 2014.
86. Hale ME, Nalamachu SR, **Khan A**. Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opioid-tolerant patients with chronic low back pain. *Pain Week* (poster), September 2011.

87. Hale ME, Nalamachu SR, **Khan A**. Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opioid-tolerant patients with chronic low back pain. *NAPA Pain Conference* (poster), September 2011.
88. Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, **Khan A**, Emslie G. A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents. *American Academy of Child and Adolescent Psychiatry Annual Meeting* (poster), October, 2011.
89. **Khan A**, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R. Changes in suicide risk and depressive symptoms with low dose lithium combined with citalopram compared to citalopram with placebo in a group of severely ill depressed patients. *50th Annual Meeting for the American College of Neuropsychopharmacology* (poster), Waikaloa, HI, December, 2011.
90. Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, **Khan A**, Emslie G. A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents. *50th Annual Meeting for the American College of Neuropsychopharmacology* (poster), Waikaloa, HI, December, 2011.
91. **Khan A**, Faucett J, Garimella R, Oquendo MA, Weisler R, Patkar AA. Completed Suicides in the United States between 1979 and 2007: Relationship to Age, Sex and Antidepressant Prescription Patterns. *Annual Meeting of the American Psychiatric Association* (poster), May 2012.
92. Khan S, Faucett J, **Khan A**. Role of patient characteristics, research design features, and mechanism of action of medication on clinical trial outcome of FDA approved medications for attention-deficit hyperactivity disorder: A review of publication bias free data of 3,843 patients. *Annual Meeting for the New Clinical Drug Evaluation Unit* (poster), June 2012.
93. Litman RE, Symialis S, **Khan A**. Are large numbers of investigative sites associated with symptom improvement on placebo in antipsychotic randomized controlled trials: A meta-analytic review. *Annual Meeting for the New Clinical Drug Evaluation Unit* (presentation), May, 2012 Annual Meeting.
94. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. *Annual Meeting of the American Psychiatric Association* (Poster), May, 2012.
95. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. *Annual Meeting of the New Clinical Drug Evaluation Unit* (Poster), May, 2012.
96. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. *Annual Meeting of the CINP World Congress of Psychopharmacology* (Poster), June, 2012.
97. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. *Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services* (Poster), August, 2012.

98. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.
99. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.
100. **Khan A**, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. U.S. Psychiatric and Mental Health Conference (Poster), November, 2012.
101. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Annual Meeting of the American Psychiatric Association (Poster), May, 2012.
102. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Annual Meeting of the New Clinical Drug Evaluation Unit (Poster), May, 2012.
103. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.
104. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Annual Meeting of the CINP World Congress of Psychopharmacology (Poster), June, 2012.
105. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services (Poster), August, 2012.
106. Edwards J, **Khan A**, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.
107. **Khan A**, Ninan PT, Ramey T, Messig M, Buckley G, Musgnung J. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients for 24 weeks with desvenlafaxine 50mg/d. Annual Meeting of the American Psychiatric Association (Poster), May, 2012.
108. **Khan A**, Ninan PT, Ramey T, Messig M, Buckley G, Musgnung J. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients for 24 weeks with desvenlafaxine 50mg/d. Annual Meeting of the Canadian Psychiatric Association (Poster), September, 2012.
109. Nalamachu S, Hale M, **Khan A**. Hydromorphone extended-release in chronic neuropathic pain. PAINWeek 2012 National Conference on Pain for Frontline Practitioners (Poster), September, 2012.
110. Nalamachu S, Hale M, **Khan A**. Hydromorphone extended-release in chronic neuropathic pain. Annual Clinical Meeting of the American Academy of Pain Management (Poster), September, 2012.
111. Bakish D, Gommoll C, Chen C, Greenberg WM, Nunez R, Liebowitz M, **Khan A**. Levomilnacipran SR 40 mg and 80 mg in Major Depressive Disorder: A Phase III, Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Study. Annual Meeting of

- the American College of Neuropsychopharmacology (Poster), Hollywood, FL; December 2012.
112. **Khan A**, Faucett J, Brown W. Differential outcome in Antidepressant Trials Among Raters from One Research Center (n=6) in Relation to Structured Interview Adherence Based on Outside Reviewer Evaluations. Annual Meeting of the New Clinical Drug Evaluation Unit (Poster), Hollywood, FL; 2013.
 113. **Khan A**, Song W, Ruth A, Edwards J, Malberg J. Efficacy and Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder: A pooled analysis of Phase III clinical trials. World International College of Neuropsychopharmacology Congress (Poster), Vancouver, CA; June, 2013.
 114. **Khan A**, Song W, Ruth A, Edwards J, Malberg J. Efficacy and Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder: A pooled analysis of Phase III clinical trials. Psych Congress Network (Poster), Las Vegas, NV; October, 2013.
 115. **Khan A**, Faucett J, Brown W. Do structured, taped and reviewed rating interviews improve outcomes in antidepressant trials? American College of Neuropsychopharmacology Annual Meeting (Poster), Hollywood, FL; December, 2013.
 116. Gommoll C, Mathews M, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. American Psychiatric Association Annual Meeting (Poster), New York, NY; May 2014.
 117. Gommoll C, Mathews M, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. American Society of Clinical Psychopharmacology Annual Meeting (Poster), Hollywood, FL; June 2014.
 118. Sanacora G, Johnson M, **Khan A**, Atkinson S, Riesenber R, Barra LA, Schronen J, Burke M, Zajecka J, Su H-L, Mathew S, Pathak S. Adjunctive lamicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: Primary results from a randomized, placebo-controlled study (PURSUIT). American Society of Clinical Psychopharmacology Annual Meeting (Poster), Hollywood, FL; June 2014.
 119. **Khan A**, Faucett J, Brown W. Magnitude of Change with Antidepressants and Placebo in Antidepressant Clinical Trials Using Structured, Taped and Appraised Rater Interviews Compared to Traditional Semi-Structured Depression Interviews. American Society of Clinical Psychopharmacology Annual Meeting (Poster), Hollywood, FL; June 2014.
 120. **Khan A**, Targum S, Detke M, Brown W. Placebo Response, Response Variance and Antidepressant-placebo Differences in Recent Antidepressant Clinical Trials Based on Three Patient Interview Models. American Society of Clinical Psychopharmacology Annual Meeting (Presentation), Hollywood, FL; June 2014.
 121. Gommoll C, Mathews M, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. CINP 2014 Annual Meeting (Poster), Vancouver, CA; June 2014.

122. Gommoll C, Mathews M, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. US Psych and Mental Health Congress Annual Meeting (Poster), Orlando, FLA; September 2014
123. Gommoll C, Mathews M, Chen D, Nunez R, **Khan A**. Efficacy and Safety of Vilazodone 20 mg and 40 mg in Major Depressive Disorder: A Randomized, Double-Blind, Placebo- and Active-Controlled Trial. ECNP Annual Meeting (Poster), Berlin, Germany; October 2014.
124. **Khan A**, Faucett J, Brown WA. Differential Pattern of Response to both Placebo and Antidepressants in Antidepressant Trials Using Two Different Rating Methods. American College of Neuropsychopharmacology Annual Meeting (Poster), Hollywood, FL; December 2014.
125. **Khan A**, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. Anxiety and Depression Conference (Poster), April 2015.
126. **Khan A**, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. American Psychiatric Association (Poster), May 2015.
127. **Khan A**, Durgam S, Tang X, Ruth A, Mathews M, Gommoll CP. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. American Society of Clinical Psychopharmacology (Poster), June 2015.
128. Kramer K, Durgam S, Chen C, Gommoll C, Edwards J, **Khan A**. Does early improvement with vilazodone predict response and remission in patients with MDD? American Psychiatric Association (Poster), June 2015.
129. **Khan A**, Zimmerman M, Fava M, Brown W. Applicability of Industry/Regulatory Antidepressant Clinical Trials to Clinical Practice. American Society of Clinical Psychopharmacology Annual Meeting (Panel Chair), May 2016.
130. **Khan A**, Faucett J, Khan Shilling S, Fahl Mar K., Brown WA. Do More Recent Antidepressant Clinical Trials Have a Higher Rate of Success? ACNP Annual Meeting (Poster), Hollywood, FL; December 2016.
128. Kramer K, Durgam S, Chen C, Gommoll C, Edwards J, **Khan A**. Does early improvement with vilazodone predict response and remission in patients with MDD? American Psychiatric Association (Poster), June 2016.
129. Kramer K, Durgam S, Chen C, Gommoll C, Edwards J, **Khan A**. Does early improvement with vilazodone predict response and remission in patients with MDD? American Society of Clinical Psychopharmacology (Poster), June 2017.
130. **Khan A**, Fahl Mar K, Khan Schilling S, Schilling J, Brown WA. The magnitude of placebo response over time for clinical trials of psychiatric and other chronic medical conditions. International Society for CNS Clinical Trials and Methodology (Poster), February 2018.

